AAMC News and Leadership Announcements, 2012 July 20

Here are the latest news updates from the AAMC.  Among the highlighted stories:

  • At long last, the field of gene therapy appears close to reaching a milestone: a regulatory approval. The European Medicines Agency has recommended approval of Glybera, which treats lipoprotein lipase deficiency.
    http://tinyurl.com/7my8g38
    http://tinyurl.com/76pykv7
  • Dr. Sally Rockey, NIH Deputy Director for Extramural Research, on Friday posted some of the data used by the ACD Working Group on Diversity in the Biomedical Research Workforce in formulating their recommendations.
    http://nexus.od.nih.gov/all/2012/07/20/diversity%e2%80%94looking-at-the-numbers/
  •  The Los Angeles Times on Thursday published an editorial opposing the proposed UC, Riverside medical school. The editorial said that “Fiscal uncertainty makes this the wrong time to embark on the ambitious new project.”
    http://tinyurl.com/7jkkpeo

Click the link below to see the full list of stories.

The University of Colorado, Denver has issued a statement concerning the suspect being held in the early Friday morning shooting that resulted in the death of 12 people and the injury of dozens of others. The statement reads, “The University of Colorado Denver – Aschutz Medical Campus can confirm that James Holmes was in the process of withdrawing from the University of Colorado Denver’s graduate program in neurosciences. Mr. Holmes enrolled at the university in June 2011. More details on James Holmes will be made available pending further investigation.” Twenty-three of the most critically injured were treated at the University of Colorado Hospital.
http://tinyurl.com/7lkll9u
http://tinyurl.com/bo9jc7f

At long last, the field of gene therapy appears close to reaching a milestone: a regulatory approval. The European Medicines Agency has recommended approval of Glybera, which treats lipoprotein lipase deficiency.
http://tinyurl.com/7my8g38
http://tinyurl.com/76pykv7

A powerful and lengthy article in Friday’s Washington Post discussed how a trio of anemia drugs — Epogen, Procrit and Aranesp — made billions for Amgen and Johnson & Johnson, but that “millions of patients had been subjected to dangerous doses that might have had little advantage.” The article, which started on page one and continued for two full pages inside the front news section, cited economic incentives embedded in the U.S. health-care system, corporate lobbying on Capitol Hill and at the FDA, and the failure of the companies to complete full safety studies for the delay in recognizing the drugs’ full dangers. The paper, however, asserts, “…at the center of any explanation of the popularity of these drugs are the nation’s doctors, clinics and hospitals, and the choices they made for patients.”
http://tinyurl.com/7jnzjkn

The HHS Office of Inspector General issued a report on Friday concerning the reporting of adverse events under state regulations. According to the IG, “We found that an estimated 60 percent of adverse and temporary harm events nationally occurred at hospitals in States with reporting systems, yet only an estimated 12 percent of events nationally met State requirements for reporting. We also found that hospitals reported only 1 percent of events.”
http://go.usa.gov/fXL

Dr. Sally Rockey, NIH Deputy Director for Extramural Research, on Friday posted some of the data used by the ACD Working Group on Diversity in the Biomedical Research Workforce in formulating their recommendations.
http://nexus.od.nih.gov/all/2012/07/20/diversity%e2%80%94looking-at-the-numbers/

The University of Michigan will establish a joint Department of Biomedical Engineering with footholds in its College of Engineering and Medical School, in an action approved by the U-M Board of Regents at its July meeting. The change takes effect Sept. 1, 2012. According to the announcement, “The department is currently housed in the College of Engineering, though its researchers regularly collaborate with medical doctors and a number of Medical School faculty hold joint appointments there. The change in academic structure is designed to bring biomedical engineering researchers closer to the patients their technologies aim to benefit, say leaders in both schools.”
http://tinyurl.com/6nwcfsd

The proposed new sampling strategy for the NIH-funded National Children’s Study has been posted.
http://tinyurl.com/d3ecpbj
http://news.sciencemag.org/scienceinsider/2012/07/nih-releases-new-design-for-chil.html

The Los Angeles Times on Thursday published an editorial opposing the proposed UC, Riverside medical school. The editorial said that “Fiscal uncertainty makes this the wrong time to embark on the ambitious new project.”
http://tinyurl.com/7jkkpeo

The Jackson Health System board has voted to put 30 percent (or $3.6 million) of its monthly payments to the University of Miami medical school into an escrow account until a final operating agreement between Jackson and UM is reached. The two institutions are currently working under a temporary MOU.
http://tinyurl.com/7bjsqw6

Susan E. Wiegers, MD, a cardiologist, has joined Temple University School of Medicine as Senior Associate Dean of Faculty Affairs and Professor of Medicine. She most recently served as Director of Clinical Echocardiography at the Hospital of the University of Pennsylvania.
http://tinyurl.com/8387yhl

Joann Boughman, Ph.D., a geneticist, has been appointed senior vice chancellor for academic affairs at the University System of Maryland (USM). Dr. Boughman is currently executive vice president of the American Society of Human Genetics and a former vice president for academic affairs and dean of the graduate school, at the University of Maryland, Baltimore (UMB). Her appointment is effective September 17, 2012.
http://www.usmd.edu/newsroom/news/1113

Tony Mazzaschi
AAMC

PS: Feel free to email <cas@aamc.org> if you have a problem accessing any article or resource mentioned in this summary. Also, have colleagues email <cas@aamc.org> if they would like to receive these news postings. We also welcome news tips and corrections.

PPS: Other news, policy, and innovation products from AAMC may be of particular interest to subscribers:
+AAMC STAT (Short, Topical and Timely), a weekly news email highlights news related to academic medicine
http://www.aamc.org/newsroom/aamcstat/aamcnews.htm (note subscription box on right)
+AAMC Washington Highlights, a weekly summary of legislative & regulatory developments affecting academic medicine
http://www.aamc.org/advocacy/washhigh/subscribe.htm
+AAMC Second Opinion, news and perspectives from AAMC’s Chief Public Policy Officer
Subscribe by emailing: SecondOpinion@aamc.org
+Wing of Zock, a blog about innovation and change in medical schools and teaching hospitals
http://wingofzock.org/ and its Twitter feed @wingofzock
+AM Express, the journal Academic Medicine’s free monthly issue announcement service
Subscribe by emailing: acadmed_online@aamc.org

PPPS: The AAMC is on both Twitter and Facebook. Access details are available at:
http://twitter.com/aamctoday
http://www.facebook.com/aamctoday

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: